Figure 1.

Patient disposition for the completed 52-week double-blind treatment period. All percentages are based on the 145 patients in the full analysis set (modified intention-to-treat population), who were included in the primary endpoint analysis. ^aOf patients not randomised, 179 did not meet the screening criteria, 7 withdrew consent, 2 experienced AEs, 1 was lost to follow-up, 1 patient was not included because of the physician’s decision, and 1 patient was not included for unspecified reason (‘other’). ^bOne patient was assigned to but did not receive ≥1 dose of each of the anifrolumab regimens and therefore was not included in the analysis. AE, adverse event; BR, basic regimen; IR, intensified regimen.